The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults
In the most comprehensive dupilumab safety assessment to date, safety was consistent with the known dupilumab safety profile. [Graphical abstract and video abstract available.] TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT03346434; NCT03345914; NCT03054428; NCT02277743; NCT02277769; NCT02260986; NCT01949311; NCT02612454. EudraCT: 2016-000955-28; 2016-004997-16; 2015-004458-16; 2014-001198-15; 2014-002619-40; 2013-003254-24; 2013-001449-15; 2015-001396-40. The Safety Data of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Infants, Children,Adolescents, and Adults(MP4 64,891 KB).
Authors
- Ana B. Rossi (ORCID: https://orcid.org/0000-0001-5345-678X)
- Ainara Rodríguez-Marco
- Zhen Chen (ORCID: https://orcid.org/0000-0002-6289-4332)
- Marius Ardeleanu (ORCID: https://orcid.org/0000-0002-7712-6862)
- Brad Shumel (ORCID: https://orcid.org/0000-0002-9285-8164)
- Anna Coleman (ORCID: https://orcid.org/0000-0002-1866-7036)
- Richard G. Langley (ORCID: https://orcid.org/0000-0003-4730-2164)
- Stephane Levy
- Ashish Bansal (ORCID: https://orcid.org/0000-0002-7371-6486)
- Faisal A. Khokhar
- Guy Gherardi
Institutions
- Dalhousie University (CA)
- Regeneron (United States) (US)
- Sanofi (Spain) (ES)
- Sanofi (United States) (US)
- Sanofi (United Kingdom) (GB)
Publication Details
- Journal
- American Journal of Clinical Dermatology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1007/s40257-025-00952-w
- Citations
- 3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.01
Funders
- Sanofi
- Regeneron Pharmaceuticals